The grant details show the name of the PI, active dates of the project, the immediate and prime sponsor and the abstract of the grant. If a abstract and title are used to create the Fingerprint of the grant. The source of grants for this application comes from authorized users entering data, so only grants entered into the system by researchers or authorized users appear in this application.
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resected Stage IV Sarcoma Patients: Support for a Randomized Phase 2 Trial
Govindaswami Ragupathi5R44CA153561-03 8/1/2010 - 1/31/2013 TDC: $ 178,241
Sponsor: Mabvax Therapeutics, Inc (National Cancer Institute)
Govindaswami Ragupathi (PD/PI)
The objective of this combined Phase I and II SBIR grant application is to evaluate for the first time the clinical efficacy of a trivalent ganglioside vaccine plus immunological adjuvant in sarcoma patients.